



## Research Article

## Proteomics-based identification of cancer-associated proteins in chronic lymphocytic leukaemia

Suliman A. Alsagaby<sup>a,b,\*</sup>, Ian A. Brewis<sup>c</sup>, Rajendran Vijayakumar<sup>d</sup>, Fahad A. Alhumaydhi<sup>e</sup>, Ameen S. Alwashmi<sup>e</sup>, Naif K. Alharbi<sup>f,g</sup>, Waleed Al Abdulmonem<sup>h</sup>, Mariappan Premanathan<sup>a</sup>, Guy Pratt<sup>i</sup>, Christopher Fegan<sup>b</sup>, Christopher Pepper<sup>b,j</sup>, Paul Brennan<sup>b</sup>

<sup>a</sup> Department of Medical Laboratories Sciences, College of Applied Medical Sciences, Majmaah University, Majmaah 11932, PO Box 1712, Saudi Arabia

<sup>b</sup> Division of Cancer & Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, United Kingdom

<sup>c</sup> TIME Institute, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, United Kingdom

<sup>d</sup> Department of Medical Laboratories Sciences, College of Applied Medical Sciences, Majmaah University, Majmaah 11932, PO Box 1712, Saudi Arabia

<sup>e</sup> Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia

<sup>f</sup> Department of Infectious Disease Research, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia

<sup>g</sup> King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

<sup>h</sup> Department of Pathology, College of Medicine, Qassim University, Buraydah, Saudi Arabia

<sup>i</sup> CRUK Institute for Cancer Studies, University of Birmingham, Vincent Drive, Edgbaston, Birmingham B15 2TT, United Kingdom

<sup>j</sup> Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom

## ARTICLE INFO

## Article history:

Received 5 August 2020

Accepted 19 April 2021

Available online 27 April 2021

## Keywords:

Biomarkers

Cancer-associated proteins

Chronic lymphocytic leukaemia

HP1BP3

Nucleolin

Proteomics

THRAP3

## ABSTRACT

**Background:** Chronic lymphocytic leukaemia (CLL) is a neoplasm of B-cells characterized by variable prognosis. Exploring the proteome of CLL cells may provide insights into the disease. Therefore, eleven proteomics experiments were conducted on eleven primary CLL samples.

**Results:** We reported a CLL proteome consisting of 919 proteins (false discovery rate (FDR)  $\leq$  1%) whose identification was based on the sequencing of two or more distinct peptides (FDR of peptide sequencing  $\leq$  1%). Mass spectrometry-based protein identification was validated for four different proteins using Western blotting and specific antibodies in different CLL samples. Small sizes of nucleolin (~57 kDa and ~68 kDa) showed a potential association with good prognosis CLL cells ( $n = 8$ ,  $p < 0.01$ ). Compared with normal B-cells, CLL cells over-expressed thyroid hormone receptor-associated protein 3 (THRAP3;  $n = 9$ ;  $p = 0.00007$ ), which is implicated in cell proliferation; and heterochromatin protein 1-binding protein 3 (HP1BP3;  $n = 10$ ;  $p = 0.0002$ ), which promotes cell survival and tumorigenesis. A smaller form of HP1BP3, which may correspond to HP1BP3 isoform-2, was specifically identified in normal B-cells ( $n = 10$ ;  $p = 0.0001$ ). HP1BP3 and THRAP3 predicted poor prognosis of CLL ( $p \leq 0.05$ ). Consistently, THRAP3 and HP1BP3 were found to be associated with cancer-related pathways ( $p \leq 0.05$ ). **Conclusions:** Our findings add to the known proteome of CLL and confirm the prognostic importance of two novel cancer-associated proteins in this disease.

**How to cite:** Alsagaby SA, Brennan P, Brewis IA, et al. Proteomics-based identification of cancer-associated proteins in chronic lymphocytic leukaemia. *Electron J Biotechnol* 2021;51. <https://doi.org/10.1016/j.ejbt.2021.04.006>

© 2021 Pontificia Universidad Católica de Valparaíso. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Introduction

Chronic lymphocytic leukaemia (CLL) is a malignant disease that affects B-cells and is characterised by a lymphocytosis of mature like B-cells that accumulate in peripheral blood, lymph

node, bone marrow and spleen [1]. CLL is predominantly a disease affecting older people; the median age of diagnosis is 70 years of age [2]. The cause of CLL is still unknown, yet some hereditary factors have been found to increase the risk of developing CLL [3]. Significant advances in CLL therapy have been accomplished yet the current treatment does not eradicate the disease but reduces the tumour burden and helps prolong patients' survival [4,5].

While genetic factors and chromosomal abnormalities play key roles in CLL [6], aberrant protein expression has been shown to

Peer review under responsibility of Pontificia Universidad Católica de Valparaíso

\* Corresponding author.

E-mail address: [s.alsagaby@mu.edu.sa](mailto:s.alsagaby@mu.edu.sa) (S.A. Alsagaby).

<https://doi.org/10.1016/j.ejbt.2021.04.006>

0717-3458/© 2021 Pontificia Universidad Católica de Valparaíso. Production and hosting by Elsevier B.V.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

heavily impact on the biology and the clinical outcomes of the disease [7]. Signalling through the B-cell receptor is a key factor for the progression of CLL [8]. Interestingly, BCR expression and signalling was shown to be strongly associated with the CLL cells carrying unmutated immunoglobulin variable heavy (*IGHV*) genes (UM-CLL) compared with those harbouring mutated *IGHV* (M-CLL) [9]. Consequently, UM-CLL is typically characterized by poor prognosis, whereas M-CLL identifies patients with a generally favourable clinical course [10,11]. Another interesting protein is zeta chain-associated protein kinase 70 (ZAP-70) that is not expressed in normal B-cells, but is highly produced in CLL cells from patients with a rapid progression of the disease, where it aberrantly participates in the signal transduction following BCR engagement [12,13,14]. Furthermore, over-expression of CD38, CXCR4, and CD49d is characteristic of enhanced migration of CLL cells to the microenvironment of lymph nodes, in which they receive proliferative and pro-survival signals, and are considered predictors of a high-risk form of the disease [15,16,17,18,19]. In contrast to normal B-cells, CLL cells exhibit an increased expression of the anti-apoptotic protein BCL-2, which among others, such as MCL-1, promote the survival of CLL cells and predict an undesirable prognosis of the disease [20,21,22]. Collectively, these findings highlight the heavy influence of aberrant protein expression on the behaviour of CLL.

Proteomics studies have been conducted on CLL cells to provide new insights into the biology of CLL by identifying new proteins with the potential to alter the pathology [23]. For example, heat shock protein 27, which inhibits apoptosis [24], was associated with high-risk CLL [25]. In addition, haematopoietic lineage cell-specific protein, which was implicated in CLL migration and tissue infiltration [26] was shown to correlate with the rapid progression of CLL [27]. Furthermore, the onco-protein T cell leukaemia/lymphoma enhances the activation of the NF- $\kappa$ B pathway and induces a CLL-like disease in transgenic mice, was reported to be highly expressed in CLL cells from patients with poor prognosis [28,29]. In a comprehensive proteomics study, increased expression of adhesion proteins, such as CD44, and decreased expression of proteins involved in the egress of CLL cells from lymph node, like adenylate cyclase-inhibiting G alpha protein and dynamin-2, were implicated in the retention of the malignant cells in the microenvironment of lymph nodes [30]. Therefore, proteomics holds great promise in being able to deepen our understanding about the aberrant protein expression associated with malignant diseases such as CLL.

In the present work we reported a CLL proteome consisting of 919 proteins with false discovery rate (FDR) = 1%. Our findings identified small sizes of nucleolin specifically in CLL cells from patients with good prognosis and detected an up-regulated expression of *THRAP3* and *HP1BP3* in CLL cells compared with normal B-cells. Consistently, high expression of *HP1BP3* and *THRAP3* was found to significantly predict poor prognosis in CLL patients.

## 2. Experimental

### 2.1. Isolation of CLL cells

Peripheral blood samples were drawn into EDTA tubes from CLL patients prior to differential blood count monitoring. The remainder of the samples (approximately 3 ml) was utilized to extract mononuclear peripheral blood cells (PBMCs) using lymphoprep (Stemcell Technologies) and gradient centrifugation. The project was approved by the South East Wales Research Ethics Committee and all clinical materials were obtained with the patients' written informed consent in accordance with the ethical approval (02/4806). CD19 positive population was assessed in the isolated

PBMCs using an Accuri C6 cytometer and CFlow software (BD) following staining with anti-human CD19 antibody conjugated to allophycocyanin (Invitrogen). Samples with less than 95% CD19 positive cells (CLL cells) were subjected to T cell depletion using CD3-magnetic beads (Invitrogen) in order to enrich for CLL cells. Viability of the samples was measured using an Annexin V apoptosis assay kit (eBioscience) and flow cytometry. Table 1 summarised the characteristics of CLL samples that were used in this study. Detailed description of the CLL samples and the disease prognosis are provided in Table S1.

### 2.2. Isolation of normal B-cells from healthy donors

Fresh buffy coat samples from healthy volunteers ( $n = 4$ ) were obtained from the Welsh Blood Service. Lymphoprep and gradient centrifugation were used to isolate PBMCs from the buffy coat samples. Assessment of the CD19 positive cells in the isolated PBMCs was conducted using an Accuri C6 cytometer and CFlow software (BD) following staining with anti-human CD19 antibody conjugated to allophycocyanin (Invitrogen). Positive isolation using CD19-magnetic beads (Invitrogen) was performed to enrich for B-cells. Next, CD19-magnetic beads were detached from the isolated cells (B-cells) using DETACHaBEADS CD19 (Invitrogen). The viability of B-cells was assessed using an Annexin V apoptosis assay kit (eBioscience) and an Accuri C6 cytometer with CFlow software (BD).

### 2.3. Cellular fractionation

Thawed cells were treated with 0.5 ml hypotonic buffer (10 mM triethylammonium bicarbonate, 1.5 mM MgCl<sub>2</sub>, and 10 mM KCl) containing 1 mM phenylmethanesulfonyl fluoride and 0.1% (v/v) Nonidet P40 (NP40) detergent for 15 min on ice. Samples were then centrifuged for 5 min (10,000  $\times$ g) at 4°C and the supernatant from each sample was transferred into another tube and labelled NP40 fractions. The remaining pellets were washed twice with 1 ml hypotonic buffer followed by centrifugation. Next, 0.2 ml 1% sodium dodecyl sulphate (SDS) solution was added and the sample was subjected to heating at 90°C for 20 min followed by sonication. This was sufficient to solubilize the washed pellets (termed SDS fractions). Protein concentrations were measured using the bicinchoninic acid assay (BCA) protein assay (Sigma).

To generate complete cell lysate, cells were resuspended in 0.2 ml 1% SDS supplemented with PMSF (final concentration 1 mM) and sonicated for 5 min. To enhance the solubilization of the cells, samples were heated at 90°C for 20 min. Following centrifugation of the samples for 5 min (10,000  $\times$ g), cellular pellet was not visible indicating complete solubilization of the cells. Protein concentration of the complete cell lysate was determined using the bicinchoninic acid assay (BCA) protein assay (Sigma).

**Table 1**  
Characteristics of the CLL patient cohort.

Factor	Subset	Number
Median Age	70	
Range	53–88	36
CD38	<20%	16
	$\geq$ 20%	20
<i>IGHV</i> status	<98%	12
	$\geq$ 98%	15
ZAP-70	<20%	9
	$\geq$ 20%	21

*IGHV* status  $\geq$  98%, ZAP-70  $\geq$  20% and CD38  $\geq$  20% are characteristics of poor prognosis. However, *IGHV* status < 98%, ZAP-70 < 20% and CD38 < 20% are predictors of good prognosis.

#### 2.4. Protein detection by gel electrophoresis and western blotting

Cellular proteins were separated by one dimensional (1D) gel electrophoresis using pre-cast NuPAGE 4–12% Bis-Tris Zoom gels (Invitrogen) under reducing conditions. For specific protein detection, proteins were transferred onto polyvinylidene fluoride membranes (GE Healthcare), probed with specific antibodies and identified using alkaline phosphatase chemiluminescent detection protocol. Antibodies against eight different proteins were applied: from Sigma anti-actin antibody (A-2066; used at 1/1000); from Abcam anti-histone H4 antibody (ab31830; used at 0.5/1000), anti-HP1BP3 antibody (ab98894; used at 1/1000) and anti-THRAP3 antibody (ab71985; used at 1/1000); from Sant Cruz Biotechnology anti-nucleolin antibody (sc-8031; used at 1/1000); from Upstate Biotechnology anti-coronin-1A antibody (#07-493; used at a 1/2000 dilution).

#### 2.5. Protein precipitation and digestion

Protein precipitation using a 2D clean up kit (GE Healthcare) was performed on identical amounts of protein (20 µg) from NP40 fraction, SDS fraction and complete cell lysate that were generated from CLL samples. Following resuspension of the precipitated proteins of NP40 and SDS fractions in 20 µL of 20 mM triethylammonium bicarbonate (TEAB) they were denatured using 1 µL of 2% SDS and reduced with 2 µL of 50 mM tris(2-carboxyethyl) phosphine (TCEP) at 60°C for 1 h. Protein alkylation was performed using 1 µL of 200 mM methylmethane-thiosulfonate in isopropanol for 10 min at room temperature. Finally, protein digestion was conducted using 2 µL of sequencing grade porcine trypsin (Promega) overnight at 37°C (the ration of enzyme/substrate = 1/20).

Precipitated proteins from the complete lysate were resuspended in 50mMTris HCl with 0.1% SDS. DTT (final concentration = 20 mM) was added to the protein suspension and samples were incubated for 10 min at 95°C. Next, iodoacetamide (IAA) was added to the samples (final concentration = 40 mM) which were incubated at room temperature in the dark for 30 min. DTT (final concentration = 10 mM) was added to the samples. For digestion, samples were incubated with 2 µL of sequencing grade porcine trypsin (Promega) overnight at 37°C (the ration of enzyme/substrate = 1/20).

#### 2.6. Separation of peptides by liquid chromatography

Peptides (13.3 µg) from NP40 and SDS fractions of CLL samples were dried using a vacuume centrifuge and then resuspended in 15 µL LC loading solution (2% (v/v) acetonitrile in water with 0.05% (v/v) trifluoroacetic acid (TFA)). Next, from the 13.3 µg peptides 9 µg was injected in a 2D nano LC system (UltiMate 30000, Dionex). Peptides from the NP40 fractions and SDS fractions were independently separated on a strong cation-exchange (SCX) column (Bio-SCX, 500 µm, 15 mm, 5 µm, Dionex) using increasing concentrations of NaCl (flow-through, 100 mM, 200 mM, 400 mM, 800 mM, and 1 M). Then, the peptide fractions were cleaned using a reverse-phase desalting column. Next the peptides were subjected to additional separation using a reverse-phase (RP) column (PepMap 75 µm i.d., 30 cm, 3 µm, 100 Å, Dionex) at a flow rate equal to 300nL/min. We used two buffers for separation on the RP column; A = 2% (v/v) ACN in water with 0.05% (v/v) TFA and B = 90% (v/v) ACN in water with 0.01% (v/v) TFA. The separation on the RP column was conducted using an increasing concentration of solvent B; from 5% to 20% for 25 min and then from 20% to 50% for 25 min. To monitor the separation profile, a chromatogram was recorded at 214 nm. A robot micro-fraction collector (Dionex) was used to spot the separated peptides (1 spot/8

seconds) onto an LC/MALDI plate. MALDI matrix  $\alpha$ -cyano-4-hydroxycinnamic acid (CHCA) (2 mg/ml CHCA in 70% (v/v) in 0.1% (v/v) TFA containing 10 fmol/ml Glu-Fib) was constantly added to the column effluent via an m-tee mixing piece at a flow rate of 1.4 ml/min.

Peptides (10 µg) from the complete cell lysate of CLL samples were dried using a vacuume centrifuge and then resuspended in 15 µL LC loading solution (2% (v/v) acetonitrile in water with 0.05% (v/v) fluoroacetic acid (FA)). Of the 10 µg peptides, 2 µg were injected into HPLC (1268 Infinity; Agilent Technologies) coupled with Chrip-Cube (Agilent Technologies). The separation was conducted on a Polaris-HR-Chip-3C18 with a 360 nl enrichment column and a 75 µm × 150 mm analytical column, which both are packed with Polaris C18-A, 180 Å, 3 µm stationary phase (Agilent Technologies). Mobile phase consisted of two puffers: A = 5% (v/v) ACN in water with 0.1% (v/v) FA and B = 95% (v/v) ACN in water with 0.1% (v/v) FA. The peptides were injected into the enrichment column using the mobile phase A at flow rate = 3 µl/min. Next, the separation of the peptide on the analytical column was performed using an increasing concentration of solvent B: 3% to 55% for 46 min and from 55% to 75% for 15 min at flow rate = 0.4 µl.

#### 2.7. Mass spectrometry analysis

Resolved peptides from the NP40 fractions and SDS fractions were analysed using an Applied Biosystems 4800 MALDI TOF/TOF mass spectrometer with a 200 Hz solid-state laser operating at a wavelength of 355 nm. The precursor masses in all LC-MALDI sample positions were measured in an MS positive reflector mode using 800 laser shots (mass range 700–3000 Da; focus mass 1400). Glu-Fib that was added to the MALDI matrix was used as an internal standard in each spot for the MS analysis. For peptide sequencing, precursor fragmentation was conducted for the most abundant six precursors with signal to noise higher than 30 in each spot position. Common trypsin autolysis peaks and matrix ion signals and precursors within 300 resolution of each other were excluded from the selection. In MS/MS positive ion mode 4000 spectra were averaged with 1 kV collision energy (collision gas was air at a pressure of 1.661026 Torr) and default calibration.

The resolved peptides from the complete cell lysate were eluted into Agilent 6540 UHD Accurate-Mass quadrupole time-of-flight (Q-TOF) mass spectrometer through electro-spray ionization (ESI) source using Agilent HPLC Chrip-Cube. The ESI was performed with a drying gas (nitrogen) at temperature of 355°C and flow rate 4 L/min. The mass spectrometry analysis was conducted at positive ion mode with a mass/charge (m/z) range of 250–3000 and five spectra/sec. Auto MS/MS of precursor ions was done with the following settings: maximum precursor per cycle was five, absolute threshold was 2000 counts and relative threshold percentage was 0.01. Active exclusion was enabled at 2 spectra and released after 1 min. Precursor charge state selection and preference were set to 2+ and then 3+.


#### 2.8. Data analysis

To perform protein identification based on peptide sequencing, the MS and MS/MS spectra from the NP40 fractions and SDS fractions were loaded into ProteinPilot 2.0.1 software (Applied Biosystems) with the Paragon and ProGroup algorithms and searched against the Human SwissProt database (release 2018(04)) that had 20,385 entries. The search was performed only against human proteins with trypsin as an enzyme used for digestion and cysteine alkylation with methyl methane-thiosulfonate. One missed cleavage was allowed. Two different scores are reported by ProteinPilot for each protein identification. First, the total protein score, which

gives a measurement of all peptides that contribute to an identification of a protein. Second, the unused protein score, which provides an assessment of only peptides that are specifically used to identify a protein but not other proteins with a higher rank. To determine the rate of incorrect protein identification, ProteinPilot 2.0.1 software was also used to run false discovery rate (FDR) analysis on the MS and MS/MS spectra. Protein identification was restricted to those that were reported with an unused protein score  $\geq 2$  with confidence threshold  $\geq 99\%$  and FDR = 1%.

The MS and MS/MS spectra generated from the complete cell lysate were loaded into Spectrum Mill Protein Identification software (Agilent Technologies) and searched against the Human SwissProt database (release 2018(04)) that had 20,385 entries. The search parameters were set as follows: protein digestion was by

trypsin, the maximum number of missed cleavages was two as recommended by the user manual provided by Agilent Technologies. Carbamidomethylation of cysteine was selected for fixed modification, and for variable modifications (oxidized methionine, pyroglutamic acid (N-termQ), phosphorylated serine, phosphorylated threonine and phosphorylated tyrosine) were selected. The precursor mass tolerance was set at  $\pm 20$  ppm and the product mass tolerance was  $\pm 50$  ppm. To ensure reporting high quality data set of CLL proteome, auto-validation of peptide sequencing and protein identification was set at FDR  $\leq 1\%$ . Only protein identifications (with protein score  $> 20$ ; FDR  $\leq 1\%$ ) based on two or more distinct peptides (with peptide score  $> 6$ ; FDR  $\leq 1\%$ ) were reported in this study.



**Fig. 1.** Schematic illustration of the proteomics workflow that was used in the present study. Following the isolation of CLL cells, they were subjected to cellular fractionation. The protein extract in the NP40 fraction, SDS fraction and complete cell lysate was independently precipitated and digested using trypsin. The resultant peptides were separately resolved by two-dimensional liquid chromatography (2D-LC; NP40 and SDS fractions) or one-dimensional liquid chromatography (1D-LC; complete cell lysate). Next, peptides were subjected to mass spectrometry analysis to determine the peptide masses (MS) and the mass of peptide fragments (MS/MS); MALDI TOF/TOF MS for NP40 and SDS fractions and ESI Q/TOF MS for complete cell lysate. The MS and MS/MS data were used to perform peptide sequencing using ProteinPilot software or Spectrum Mill Protein Identification software with the Human SwissProt (protein) database in order to identify proteins.

## 2.9. Transcriptomics data sets

Two independent transcriptomics data sets of CLL (accession number: GSE22762 [31] and GSE39671 [32]) from GEO <http://www.ncbi.nlm.nih.gov/geo/> were used for the analysis that aimed to investigate the prognostic potential of *THRAP3*, *HP1BP3* in CLL patients. Three reasons led to the selection of these two data sets. First, they included information about the clinical outcomes of the disease; GSE22762 contained data about overall survival (OS) and GSE39671 included information about time to first treatment (TTFT). Second, the two data sets were based on independent cohorts containing more than 100 patients each. Third, both data sets were generated using the same oligonucleotide microarray platform (Affymetrix Human Genome U133 Plus 2.0 Array). The DataSet SOFT files of the transcriptomics data sets were downloaded from GEO and used.

## 2.10. Statistical analysis

Protein scores (total and unused), FDR and confidence threshold of protein identification (in NP40 and SDS fractions) were calculated using ProteinPilot 2.0.1 software (Applied Biosystems) with the Paragon and ProGroup algorithms. Spectrum Mill Protein Identification software (Agilent Technologies) was used to calculate the score and FDR of peptides and proteins identified in the complete cell lysate. Prism software (graphpad) was also employed to construct Kaplan-Meier curves and to calculate *p*-values with hazard ratios (HRs) based on the long-rank test. Column graphs were prepared using Excel software and the associated *p*-values were calculated using the unpaired Student's *t*-test. Heatmap was constructed using the heatmap tool (<http://heatmap.ca/>) [33]. Pathway enrichment analysis and the associated *p* values were calculated using "Reactome Pathway Database" (<https://reactome.org/>) [34].

## 3. Results

### 3.1. Proteomics analysis

In the current study, we performed 11 proteomics experiments on 11 CLL samples with variable prognosis. Information about the prognostic markers of the 11 CLL samples is shown in Table S1. Six proteomics experiments (2D nano-LC with MALDI TOF/TOF MS) were conducted on the NP40 and SDS fractions from six CLL samples. Next, five proteomics experiments (1D nano-LC with ESI Q/TOF MS) were done on complete cell lysate generated from 5 CLL samples. The utilized proteomics workflow is illustrated and summarised in Fig. 1. We identified 359 proteins in the NP40 fractions and 142 proteins in the SDS fractions (73 proteins were common in both fractions; total number of proteins = 428). Table S2, Table S3, Table S4, Table S5 and Table S6 show the full list of the reported proteins and the peptides used for protein identifications. The 428 proteins were identified using two or more distinct peptides with a minimum unused protein score = 2 (confidence threshold  $\geq 99\%$  and FDR = 1%). From the complete cell lysate of five CLL samples we reported 718 proteins (Table S6 and Table S7). The protein identification was based on two or more distinct peptide with peptide score > 6 (FDR  $\leq 1\%$ ) and protein score > 20 (FDR  $\leq 1\%$ ). Collectively, our study reported a CLL proteome consisting of 919 proteins with FDR  $\leq 1\%$  (Table 2).

Our study identified 359 proteins in the NP40 fractions and 142 proteins in the SDS fractions; 73 proteins were common in the two fractions (Fig. 2A). To explore the type of protein enrichment in the NP40 fractions and in the SDS fractions, we used Gene Ontology (GO) data coupled with Quick GO tool (<https://www.ebi.ac.uk/>


QuickGO/) [35]. Proteins specific to the NP40 fractions and to the SDS fractions were annotated to one or more of the following GO terms "cytosol, membrane, mitochondrion or nucleus". The analysis revealed that cytosolic proteins were more predominant in the NP40 fractions, while nuclear proteins dominated the SDS fractions (Fig. 2B).

### 3.2. Validation of the proteomics findings

Our proteomics work reported a CLL proteome consisting of 919 proteins (FDR  $\leq 1\%$ ). To confirm the mass spectrometry-based protein identification, the detection of four proteins was validated in CLL samples using Western blotting and specific antibodies. The proteomics data showed that HP1BP3, histone H4, coronin-1A and nucleolin were identified in CLL cells with multiple peptides ( $n \geq 3$ ), unused protein score  $\geq 5.8$  and sequence coverage  $\geq 9.4\%$ .


**Table 2**  
Summary of the protein identifications in the three types of protein extract using different proteomic instruments.

Type of protein extract	Instruments	Size of identified proteome
NP40 fraction	2D nano-LC with MALDI TOF/TOF MS	359 proteins
SDS fraction	2D nano-LC with MALDI TOF/TOF MS	142 proteins
Complete cell lysate	1D nano-LC with ESI Q/TOF MS	718 proteins
All the three types of protein extract (NP40 fraction, SDS fraction and complete cell lysate)	2D nano-LC with MALDI TOF/TOF MS and 1D nano-LC with ESI Q/TOF MS	919 proteins



**Fig. 2.** Venn diagram and protein localization analyses of the reported proteins. Venn diagram shows common and specific proteins in the NP40 fractions and SDS fractions (A). Gene Ontology, coupled with Quick GO tool, was used to determine the type of protein enrichment in the NP40 fractions and SDS fractions (B).





**Fig. 3.** Validation of the proteomics findings. Western blotting with specific antibodies was used to confirm the mass spectrometry-based protein identification. HP1BP3 (A) and Histone H4 (B) were investigated in SDS fractions of CLL samples. Coronin-1A (C) and nucleolin (D-G) were analysed in NP40 fractions of CLL samples. N: NP40 fraction; S: SDS fraction; Pep. #: peptide count that was used for protein identification by mass spectrometry; score: unused protein score; %Seq.: percentage of protein sequence coverage; Frac: fraction in which a protein was identified by mass spectrometry; GP: good prognosis (for the patients: P26, P28 and P29); PP: poor prognosis (for the patients: P1, P3, P27, P25 and P30).

The validation analyses of these proteins in CLL samples ( $n = 8$  for each protein) using specific antibodies agreed with the mass spectrometry findings (Figs. 3A–4D). Lower molecular weight bands of nucleolin (two bands: ~57 kDa and ~68 kDa) were predominantly detected in CLL samples from patients at the early stage of the disease (stage A) and with good prognostic markers (M-CLL and ZAP-70 negative;  $n = 8, p \leq 0.008$ , Fig. 3D, Fig. 3E and Fig. 3F respectively). These data may propose a potential association of the small size nucleolin with good prognosis of CLL. This finding was also associated with a decreased ratio of the full-length nucleolin (110 kDa) to actin in CLL cells from patients with good prognosis ( $n = 8, p = 0.05$ , Fig. 3D and 3G).




### 3.3. CLL-associated proteins

CLL cells were previously shown to upregulate the expression of RNA processing proteins. Therefore, we studied the expression of

the RNA processing proteins (THRAP3 and HP1BP3) in CLL cells versus normal B-cells. Our proteomics data set showed that THRAP3 was detected specifically in SDS fractions with 3 different peptides, unused protein score = 6 and sequence coverage = 6.8. The identification details of HP1BP3 by mass spectrometry were mentioned earlier.




It has been controversial what defines the best normal counterpart to CLL cells, with B-cells expressing CD19, CD5, CD23 and TLR9 being suggested as good normal match of CLL cells [36]. CD5+ normal B-cells with or without CD23 and TLR9 represent a small proportion of normal B-cells population (approximately 15%) [37], thus larger volume of samples and extensive cell sorting are required to isolate sufficient number of CD5 B-cells for western blotting analysis. As a result, this restricted us to the use of CD19+ B-cells from the peripheral blood of healthy donors as a normal control of CLL cells.

The isolation of normal B-cells from four healthy donors began with the isolation of peripheral blood mononuclear cells (PBMCs)



**Fig. 4.** CLL-associated proteins. Four normal B-cells samples were isolated from buffy coat of four healthy donors (A and B). Western blotting and specific antibodies were used to investigate the expression of THRAP3 and HP1BP3 in CLL samples (P31, P32, P33, P34, P35 and P36) and normal B-cells (N1-N4; C-G). Alternative splicing is known to produce four isoforms of HP1BP3; the amino acid sequence (71\*\*\*\*\*120) is the region of the protein that the anti-HP1BP3 antibody (ab98894) identifies (H). SSC: side-scattered light; FSC: forward-scattered light; LP: lymphocyte population.


from buffy coat samples. Subsequent flow cytometric analysis showed that further enrichment of B-cells was required (average CD19+ cells = 5%; standard deviation = 2%; Fig. 4A). Next, positive purification of B-cells was conducted using CD19-magnetic beads followed by DETACHaBEADS CD19 reagents to remove the beads from the isolated B-cells. This step resulted in an enrichment of the CD19+ population (CD19+ cells ≥ 85%; Fig. 4B).



0.22 in normal B-cells ( $n = 10$ ;  $p = 0.0002$ ; Fig. 4D and Fig. 4F). Interestingly, the anti-HP1BP3 antibody (ab98894) detected a smaller size of HP1BP3 (~57 kDa) specifically in the normal B-cells, but not in the CLL cells ( $n = 10$ ,  $p = 0.0001$ ; Fig. 4D and Fig. 4G). Alternative splicing was reported to produce 4 different isoforms of HP1BP3, which are documented at the level of protein in the UniProt knowledgebase (<https://www.uniprot.org/>). Fig. 4H shows a representation of these isoforms and the region that is targeted by the anti-HP1BP3 antibody (ab98894) that was used in this study. Therefore, the small size of HP1BP3 (~57 kDa) detected specifically in normal B-cells is likely to be the isoform 2 of the protein.


Public repositories like GEO represent rich sources of omics data sets that can be used to investigate the relation between a gene of interest and a disease [38,39]. Therefore, two independent transcriptomics data sets of CLL (GSE22762 and GSE39671) from GEO with clinical details about overall survival (OS) or time-to-first-treatment (TTFT) were used to investigate whether the transcript expression of *THRAP3* and *HP1BP3* could be relevant to CLL prognosis. Initially the median expression of the transcripts corresponding to *HP1BP3* and *THRAP3* in each data set was used to divide the patients into two groups: a low expression group, where the expression of *THRAP3* and *HP1BP3* was below the median, and a high expression group, where the expression of *HP1BP3* and *THRAP3* was above the median. Next, the OS and TTFT data were compared in the low and high expression groups of the two data sets using Kaplan-Meier curve. The analysis showed that the median expression of *THRAP3* and *HP1BP3* did not significantly segregate CLL patients into two groups with different prognosis. Therefore, an effort was made using the “Cutoff Finder” tool (<http://molpath.charite.de/cutoff/>) [40] to search for a cutoff value (z-score) of the expression of *THRAP3* and *HP1BP3* that significantly predicts the prognosis of CLL patients. As a result, an increased expression of *HP1BP3* (above a cutoff value: z-score = 0.41) was found to predict early need of therapy ( $n = 121$ ,  $p = 0.008$ , HR = 2.10, Fig. 5A). Likewise, high expression of *THRAP3* identified patients with early treatment (z-score = 0.21,  $n = 121$ ,  $p = 0.05$ , HR = 1.70, Fig. 5B) and short overall survival (z-score = 0.57,  $n = 107$ ,  $p = 0.005$ , HR = 3.80, Fig. 5C).

Next, we attempted to explain the association of *THRAP3* with poor prognosis of CLL by employing Pearson score (PS) to identify genes that correlated with the expression of *THRAP3* in CLL cells from 130 patients (data set GSE39671). Correlation with the expression of *THRAP3* was detected for 210 genes ( $PS \geq 0.40$ ;  $p < 0.00001$ ). Interestingly, some of these genes play roles in cell division and tumor growth, such as cell division cycle 14A (*CDC14A*), cell division cycle 40 (*CDC40*), cell cycle associated protein 1 (*CAPRIN1*), microtubule-associated protein 9 (*MAP9*), fibroblast growth factor receptor 1 (*FGFR1*), SRC proto-oncogene tyrosine kinase (*SRC*) and Src homology 2 domain containing adaptor protein B (*SHB*) and Kirsten rat sarcoma viral oncogene homolog (*KRAS*) (Fig. 6A). To gain insights into the functional roles of the 210 genes, we performed pathway enrichment analysis using “Reactome Pathway Database”. The analysis found a significant enrichment by the 210 genes for cancer-related pathways like *FGFR1* signalling, *RAS* signalling and *VEGFR2* mediated cell proliferation (Table 3). Following the same concept, we employed PS to identify genes that exhibited correlation with the expression of *HP1BP3* in CLL cells using the data set GSE39671. The analysis found 2223 genes to be correlated with the expression of *HP1BP3* in 130 CLL patients ( $PS \geq 0.40$ ;  $p < 0.00001$ ). Fig. 6B shows the correlation between *HP1BP3* and known CLL-related genes, such as *CD79B*, B-cell linker (*BLNK*), bruton tyrosine kinase (*BTIK*), T-cell leukemia/lymphoma 1A (*TCL1A*) and *CD40*. Utilizing “Reactome Pathway Database” we conducted pathway enrichment analysis of the 2223 genes (Table 3).



**Fig. 5.** Investigations of the prognostic potential of *THRAP3* and *HP1BP3* in CLL. Two data sets of CLL from GEO were used (GSE22762 and GSE39671). Low expression was defined as patients with expression of *THRAP3* or *HP1BP3*  $<$  a z-score; high expression of *THRAP3* or *HP1BP3* was defined as  $>$  a z-score. The z-scores 0.41, 0.20, 0.57 were used for the analyses of *HP1BP3* with TTFT (A), *THRAP3* with TTFT (B) and *THRAP3* with OS (C), respectively. UD: undefined; HR: hazard ratio of high expression versus low expression.





**Fig. 6.** Heatmap presentation of the correlation of *THRAP3* and *HP1BP3* with other genes in CLL cells from 130 patients. The analysis was conducted on the data set GSE39671; the Pearson score (PS) ranged from 0.40 to 0.58 for *THRAP3* (A) and 0.51 to 0.76 for *HP1BP3* (B) with *p* value less than 0.00001. Green is high expression and red is low expression.

#### 4. Discussion

Proteomics is a useful approach to study aberrant protein expression in CLL in order to provide novel insights into the pathology of the disease [23]. The dynamic range of cellular proteins was reported to reach six-fold [41]. Therefore, cellular fractionation was previously described as an effective method to increase the

chance of identifying larger number of proteins using gel-free based proteomic approaches [42,43,44,45]. Following the same concept, we performed cellular fractionation on CLL cells (NP40 fractions and SDS fractions). The NP40 fractions appeared to be enriched with cytosolic proteins, whereas the SDS fractions were enriched with nuclear proteins. For example, only one histone protein (nuclear protein) was detected in the NP40 fraction. In

**Table 3**  
Pathway enrichment analysis of genes that correlated with *THRAP3* or *HP1BP3*.

Pathway name	No of genes found	No of genes in total	p value	Analysis
SHC-mediated cascade:FGFR1	4	30	0.002	<i>THRAP3</i>
FRS-mediated FGFR1 signaling	4	31	0.002	<i>THRAP3</i>
Signaling by FGFR1 in disease	5	58	0.003	<i>THRAP3</i>
Signaling by FGFR1	5	62	0.004	<i>THRAP3</i>
Signalling to RAS	3	26	0.010	<i>THRAP3</i>
Signaling by RAS mutants	4	54	0.014	<i>THRAP3</i>
Signaling by moderate kinase activity BRAF mutants	4	54	0.014	<i>THRAP3</i>
Signaling downstream of RAS mutants	4	54	0.014	<i>THRAP3</i>
Activation of RAS in B cells	2	11	0.015	<i>THRAP3</i>
VEGFR2 mediated cell proliferation	3	31	0.016	<i>THRAP3</i>
Signaling by EGFR	4	61	0.020	<i>THRAP3</i>
Signaling by Insulin receptor	5	97	0.025	<i>THRAP3</i>
RAF activation	3	37	0.025	<i>THRAP3</i>
Signalling to ERKs	3	42	0.035	<i>THRAP3</i>
Synthesis of DNA	54	132	0.000002	<i>HP1BP3</i>
DNA Replication	55	141	0.000006	<i>HP1BP3</i>
S Phase	64	179	0.00002	<i>HP1BP3</i>
mRNA Splicing	64	196	0.0002	<i>HP1BP3</i>
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha	26	72	0.004	<i>HP1BP3</i>
Downstream signaling events of B Cell Receptor (BCR)	31	93	0.006	<i>HP1BP3</i>
Extension of Telomeres	21	62	0.02	<i>HP1BP3</i>
Activation of NF-kappaB in B cells	23	72	0.02	<i>HP1BP3</i>
Cell Cycle	167	715	0.03	<i>HP1BP3</i>

"Reactome Pathway Database" was employed to perform pathway enrichment analysis. "No of genes found" indicates the number of genes that correlated with *THRAP3* or *HP1BP3* and were assigned to a pathway. "No of genes in total" is the number of all known genes that function in a pathway.

contrast, 13 different histone proteins were identified in the SDS fractions. In the complete cells lysate preparation, only 4 histone proteins were identified, although the proteomics experiments were conducted using Agilent 6540 UHD Accurate-Mass Q-TOF mass spectrometer, which yielded larger proteome identifications compared with Applied Biosystems 4800 MALDI TOF/TOF mass spectrometer. Although the size of the proteome detected in the SDS fractions was small (142 proteins), working on SDS fractions seemed justifiable when DNA-associated proteins are of interest.

The good quality of our CLL proteome was evident at the validation analyses. The specific antibody-based protein identification of all examined proteins ( $n = 4$ ) in CLL samples was consistent with the proteomics findings, adding more validity to the reported CLL proteome.

Nucleolin (110 kDa) is a pro-survival protein that stabilizes the transcript of BCL-2 in CLL cells and inhibits FAS-induced apoptosis in B-cell lymphomas [46,47]. In CLL cells, the expression of nucleolin positively correlates with the level of BCL-2, supporting the conception that nucleolin is a stabilizing protein of BCL-2 mRNA [47]. The same study also showed that in contrast to normal B-cells, CLL cells over-express both nucleolin and BCL-2. As an anti-apoptotic protein BCL-2 is one of the main drivers of the survival of CLL cells and is considered a marker of poor prognosis in CLL patients [20]. Our preliminary data ( $n = 8$ ) showed lower abundance of the intact nucleolin (110 kDa) that was associated with the detection of small sizes of the protein (~68 kDa and ~57 kDa) in CLL cells from patients with good prognosis. These findings might indicate an active degradation of nucleolin (110 kDa) in CLL cells from patients with good prognosis compared with those from patients with poor prognosis. The stability of nucleolin (110 kDa) has been shown to be proliferation-dependent [48]. In proliferating peripheral blood lymphocytes (PBLs) nucleolin (110 kDa) was the main detected band, whereas smaller sizes of nucleolin (68 kDa, ~57 kDa and 43 kDa) were predominantly found in less proliferative or non-dividing PBLs [48]. Given the roles of nucleolin (110 kDa) in the survival and proliferation, our findings are in consistence with the phenotype of good prognosis of CLL. Furthermore, our data may provide an explanation, at least partially, for the lower capacity of good prognosis CLL cells to undergo proliferation and resist apoptosis compared

with poor prognosis CLL cells [49]. The sample size we used to study nucleolin was small ( $n = 8$ ). Therefore, studying the expression of nucleolin in a larger number of CLL samples is required to confirm our finding.

In the present study, *THRAP3*, which is an RNA processing protein, was found with high expression in CLL cells compared with normal B-cells. This finding supports a recently published work, where CLL cells were shown to over-express proteins implicated in mRNA processing [50]. *THRAP3* plays role in the cell cycle progression, where it is required for the production of mature transcript of cyclin D1 [51]. CLL cells that express cyclin D1 were shown to reside in the proliferation centre in lymph nodes, indicating a role of cyclin D1 in the proliferation of CLL cells [52]. In contrast to the historical view, that described CLL as a dysfunctional apoptosis-driven disease, CLL is currently viewed as a dynamic cancer composed of malignant cells with variable rates of proliferation and apoptosis [49]. In fact, CLL cells have a prolonged proliferation history compared with normal B-cells as evidenced by the shorter telomeres of the malignant cells [53]. Given the role of *THRAP3* on the progression of cell cycle, its increased expression in CLL cells may support their expansion. Interestingly, CLL cells harboring unmutated *IGHV* (poor prognostic marker) were found to up-regulate the expression of *THRAP3* compared with those carrying mutated *IGHV* (good prognostic marker) [30]. In line with this view, using data sets of CLL transcriptomics from GEO, we showed that high expression of *THRAP3* mRNA is predictive of early treatment and short overall survival in CLL patients in two independent transcriptomics data sets (total number of CLL patients = 228). In agreement with this finding, we also found genes that have been implicated in cell division and tumour growth, such as *CDC14A* [54], *CDC40* [55], *CAPRIN1* [56], *MAP9* (also known as *ASAP*) [57], *FGFR1* [58], *SRC* [59], *KRAS* [60], and *SHB* [61] to significantly correlate with the expression of *THRAP3* in CLL cells. These results may provide rationale for the prediction of poor prognosis of CLL by the high expression of *THRAP3*.

Our study identified a specific expression of a smaller form (~57 kDa) of *HP1BP3* in normal B-cells compared with CLL cells. *HP1BP3* has four isoforms that result from alternative splicing that were documented at the level of protein in UniProt knowledge base (<https://www.uniprot.org/>). The anti-*HP1BP3* antibody

(ab98894) used in this study targets a peptide sequence within the N terminal (amino acids: 71–120) of the protein. This sequence is present in HP1BP3 isoform 1 (size = 67 kDa), isoform 2 (size = 57 kDa) and isoform 4 (size = 15 kDa). It is possible that the HP1BP3 (~57 kDa), specifically detected in normal B-cells, corresponds to isoform 2. Therefore, this finding proposes HP1BP3 (~57 kDa) as a marker to aid in the differentiation between normal B-cells and CLL cells. Examining HP1BP3 (~57 kDa) in a larger number of CLL and normal B-cell samples would seem worthwhile in order to draw a definitive conclusion about its possible utility as a diagnostic marker.

The expression of the intact form of HP1BP3 (67 kDa) was higher in CLL cells compared with normal B-cells. HP1BP3 is implicated in cellular proliferation, where it maintains heterochromatin integrity during G1 to S phase of the cell cycle affecting the duration of G1 phase [62]. In addition, HP1BP3 is a pro-survival protein; it mediates chromatin condensation that protects cells from hypoxia-induced apoptosis [63]. Furthermore, HP1BP3 increases the tumorigenesis of malignant cells. For example, HP1BP3-deficient cancer cells (A341) produced tumours in 50% of injected mice, whereas A341 cells expressing HP1BP3 induced tumor growth in all tested mice and the tumor was bigger and more resistant to chemotherapy in mice that received HP1BP3 expressing A341 cells [63]. Consistent with the known roles of HP1BP3, our data showed that high expression of HP1BP3 transcript was predictive of shorter time to first treatment in CLL patients. In line with this finding, our correlation analysis identified an association between the expression of *HP1BP3* and others genes that enriched for CLL-related pathways such as cell cycling [49], BCR signaling [9], activation of NF- $\kappa$ B [64] and extension of telomeres [53]. Taken together, these findings suggest a role of HP1BP3 in the growth and survival of CLL cells.

## 5. Conclusions

Overall, our study adds to the known proteome of CLL. Nucleolin, THRAP3 and HP1BP3 are proteins that were implicated in cellular proliferation and survival; and appeared in our study to be CLL-associated proteins and/or predict the prognosis of the neoplasm. Therefore, our findings provide a rationale for further investigations on these proteins using a bigger number of samples to determine their roles in CLL with the view of novel biomarkers and targeted therapy.

## Ethical approval

The present study was approved by the South East Wales Research Ethics Committee and all clinical materials were obtained with the patients' written informed consent in accordance with the ethical approval (02/4806).

## Conflicts of interest

The authors declare no conflict of interest.

## Financial support

The authors would like to thank the Deanship of Scientific Research at Majmaah University in Saudi Arabia for supporting this work under Project Number [R-2021-1].

## Acknowledgments

The authors would like to thank the Cardiff University Central Biotechnology Service (CBS), Proteomic Facility.

## Supplementary material

<https://doi.org/10.1016/j.ejbt.2021.04.006>.

## References

- [1] Dighiero G. CLL biology and prognosis. *Hematology Am Soc Hematol Educ Program* 2005;1:278–84. <https://doi.org/10.1182/asheducation-2005.1.278> PMID: 16304392.
- [2] Montserrat E, Bosch F, Rozman C. B-cell chronic lymphocytic leukemia: Recent progress in biology, diagnosis, and therapy. *Ann Oncol* 1997;8(1):S93–S101. [https://doi.org/10.1093/annonc/8.suppl\\_1.S93](https://doi.org/10.1093/annonc/8.suppl_1.S93) PMID: 9187440.
- [3] Fabbri G, Dalla-Favera R. The molecular pathogenesis of chronic lymphocytic leukaemia. *Nat Rev Cancer* 2016;16(3):145–62. <https://doi.org/10.1038/nrc.2016.8> PMID: 26911189.
- [4] Shustik C, Bence-Bruckler I, Delage R, Owen CJ, Toze CL, Coutre S. Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia. *Ann Hematol* 2017;96(7):1185–96. <https://doi.org/10.1007/s00277-017-2982-1> PMID: 28389687.
- [5] Bose P, Gandhi V. Recent therapeutic advances in chronic lymphocytic leukemia. *F1000Research* 2017;6:1924. <https://doi.org/10.12688/f1000research.11618.1> PMID: 29152232.
- [6] Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. *N Engl J Med* 2000;343(26):1910–6. <https://doi.org/10.1056/NEJM200012283432602> PMID: 11136261.
- [7] Alsagaby SA, Brennan P, Pepper C. Key Molecular drivers of chronic lymphocytic leukemia. *Clinical Lymphoma Myeloma Leukemia* 2016;16(11):593–606. <https://doi.org/10.1016/j.clml.2016.08.008> PMID: 27601002.
- [8] Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. *Blood* 2012;120(6):1175–84. <https://doi.org/10.1182/blood-2012-02-362624> PMID: 22715122.
- [9] Stevenson FK, Krysov S, Davies AJ, et al. B-cell receptor signaling in chronic lymphocytic leukemia. *Blood* 2011;118(16):4313–20. <https://doi.org/10.1182/blood-2011-06-338855> PMID: 21816833.
- [10] Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. *Blood* 1999;94(6):1848–54. <https://doi.org/10.1182/blood.V94.6.1848> PMID: 10477713.
- [11] Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. *Blood* 1999;94(6):1840–7. <https://doi.org/10.1182/blood.V94.6.1840> PMID: 10477712.
- [12] Chan AC, Van Oers N, Tran A, et al. Differential expression of ZAP-70 and Syk protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling. *J Immunol* 1994;152(10):4758–66. PMID: 8176201.
- [13] Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. *Blood* 2002;100(13):4609–14. <https://doi.org/10.1182/blood-2002-06-1683> PMID: 12393534.
- [14] Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. *New England J Med* 2004;351(9):893–901. <https://doi.org/10.1056/NEJMoa040857> PMID: 15329427.
- [15] Deaglio S, Aydin S, Grand MM, et al. CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells. *Mol Med* 2010;16(3–4):87–91. <https://doi.org/10.2119/molmed.2009.00146> PMID: 19956559.
- [16] Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. *Blood* 1999;94(11):3658–67. <https://doi.org/10.1182/blood.V94.11.3658> PMID: 10572077.
- [17] Majid A, Lin TT, Best G, et al. CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. *Leuk Res* 2011;35(6):750–6. <https://doi.org/10.1016/j.leukres.2010.10.022> PMID: 21093051.
- [18] Ibrahim S, Keating M, Do K-A, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. *Blood* 2001;98(1):181–6. <https://doi.org/10.1182/blood.V98.1.181> PMID: 11418478.
- [19] Bulian P, Shanafelt TD, Fegan C, et al. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. *J Clin Oncol* 2014;32(9):897–904. <https://doi.org/10.1200/JCO.2013.50.8515> PMID: 24516016.
- [20] Pepper C, Lin TT, Pratt G, et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. *Blood* 2008;112(9):3807–17. <https://doi.org/10.1182/blood-2008-05-157131> PMID: 18599795.
- [21] Hanada M, Delia D, Aiello A, et al. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. *Blood* 1993;82(6):1820–8. <https://doi.org/10.1182/blood.V82.6.1820> PMID: 8104532.
- [22] McCarthy BA, Boyle E, Wang XP, et al. Surface expression of Bcl-2 in chronic lymphocytic leukemia and other B-cell leukemias and lymphomas without a breakpoint t(14; 18). *Mol Med* 2008;14(9–10):618–27. <https://doi.org/10.2119/2008.00061.McCarthy> PMID: 18633450.
- [23] Alsagaby SA, Alhumaydhi FA. Proteomics insights into the pathology and prognosis of chronic lymphocytic leukemia. *Saudi Med J* 2019;40(4):317–27. <https://doi.org/10.15537/smj.2019.4.23598> PMID: 30957124.



- [24] Chen X, Dong XS, Gao HY, et al. Suppression of HSP27 increases the anti-tumor effects of quercetin in human leukemia U937 cells. *Mol Med Report* 2016;13(1):689–96. <https://doi.org/10.3892/mmr.2015.4600> PMID: 26648539.
- [25] Voss T, Ahorn H, Haberl P, et al. Correlation of clinical data with proteomics profiles in 24 patients with B-cell chronic lymphocytic leukemia. *Int J Cancer* 2001;91(2):180–6. [https://doi.org/10.1002/1097-0215\(200002\)9999:9999<::AID-IJC1037>3.0.CO;2-J](https://doi.org/10.1002/1097-0215(200002)9999:9999<::AID-IJC1037>3.0.CO;2-J).
- [26] Scielzo C, Bertilaccio MT, Simonetti G, et al. HS1 has a central role in the trafficking and homing of leukemic B cells. *Blood* 2010;116(18):3537–46. <https://doi.org/10.1182/blood-2009-12-258814> PMID: 20530793.
- [27] Perrot A, Pionneau C, Nadaud S, et al. A unique proteomic profile upon surface IgM ligation in unmutated chronic lymphocytic leukemia. *Blood* 2011;118(4):e1–e15. <https://doi.org/10.1182/blood-2011-02-335125> PMID: 21602524.
- [28] Gaudio E, Spizzo R, Paduano F, et al. Tcl1 interacts with Atm and enhances NF- $\kappa$ B activation in hematologic malignancies. *Blood* 2012;119(1):180–7. <https://doi.org/10.1182/blood-2011-08-374561> PMID: 22065599.
- [29] Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. *Proc Natl Acad Sci* 2002;99(10):6955–60. <https://doi.org/10.1073/pnas.102181599> PMID: 12011454.
- [30] Eagle GL, Zhuang J, Jenkins RE, et al. Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (ighv)-unmutated chronic lymphocytic leukemia. *Mol Cell Proteomics* 2015;14(4):933–45. <https://doi.org/10.1074/mcp.M114.044479> PMID: 25645933.
- [31] Herold T, Jurinovic V, Metzeler KH, et al. An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. *Leukemia* 2011;25(10):1639–45. <https://doi.org/10.1038/leu.2011.125> PMID: 21625232.
- [32] Chuang H-Y, Rassenti L, Salcedo M, et al. Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. *Blood* 2012;120(13):2639–49. <https://doi.org/10.1182/blood-2012-03-416461> PMID: 22837534.
- [33] Babicki S, Arndt D, Marcu A, et al. Heatmapper: web-enabled heat mapping for all. *Nucleic Acids Res* 2016;44(W1):W147–53. <https://doi.org/10.1093/nar/gkw419> PMID: 27190236.
- [34] Croft D, Mundo AF, Haw R, et al. The Reactome pathway knowledgebase. *Nucleic Acids Res* 2014;42(D1):D472–7. <https://doi.org/10.1093/nar/gkt1102> PMID: 24243840.
- [35] Binns D, Dimmer E, Huntley R, et al. QuickGO: a web-based tool for Gene Ontology searching. *Bioinformatics* 2009;25(22):3045–6. <https://doi.org/10.1093/bioinformatics/btp536> PMID: 19744993.
- [36] Darwiche W, Gubler B, Marolleau J-P, et al. Chronic lymphocytic leukemia B-cell normal cellular counterpart: clues from a functional perspective. *Front Immunol* 2018;9:683. <https://doi.org/10.3389/fimmu.2018.00683> PMID: 29670635.
- [37] Dono M, Cerruti G, Zupo S. The CD5+ B-cell. *Int J Biochem Cell Biol* 2004;36(11):2105–11. <https://doi.org/10.1016/j.biocel.2004.05.017> PMID: 15313456.
- [38] Alsagaby SA. Integration of proteomics and transcriptomics data sets identifies prognostic markers in chronic lymphocytic leukemia. *Majmaah J Health Sci* 2019;7(1):1–22. <https://doi.org/10.5455/mjhs.2019.01.002>.
- [39] Alsagaby SA. Transcriptomics-based validation of the relatedness of heterogeneous nuclear ribonucleoproteins to chronic lymphocytic leukemia as potential biomarkers of the disease aggressiveness. *Saudi Med J* 2019;40(4):328–38. <https://doi.org/10.15537/smi.2019.4.23380> PMID: 30957125.
- [40] Budczies J, Klauschen F, Sinn BV, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. *PLoS One* 2012;7(12). <https://doi.org/10.1371/journal.pone.0051862> PMID: 23251644.
- [41] Ponomarenko EA, Poverennaya EV, Ilgisonis EV, et al. The size of the human proteome: the width and depth. *Int J Anal Chem* 2016;2016:7436849. <https://doi.org/10.1155/2016/7436849> PMID: 27298622.
- [42] Yates JR, Ruse CI, Nakorchevsky A. Proteomics by mass spectrometry: approaches, advances, and applications. *Annu Rev Biomed Eng* 2009;11(1):49–79. <https://doi.org/10.1146/annurev-bioeng-061008-124934> PMID: 19400705.
- [43] Drissi R, Dubois ML, Boisvert FM. Proteomics methods for subcellular proteome analysis. *FEBS J* 2013;280(22):5626–34. <https://doi.org/10.1111/febs.12502> PMID: 24034475.
- [44] Stasyk T, Huber LA. Zooming in: fractionation strategies in proteomics. *Proteomics* 2004;4(12):3704–16. <https://doi.org/10.1002/pmic.200401048> PMID: 15540207.
- [45] Alsagaby SA. Understanding the fundamentals of proteomics. *Curr Top Pept Protein Res* 2019;20(3):25–33. <https://doi.org/10.31300/CTPPR.20.2019.25-33>.
- [46] Wise JF, Berkova Z, Mathur R, et al. Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex. *Blood* 2013;121(23):4729–39. <https://doi.org/10.1182/blood-2012-12-471094> PMID: 23599269.
- [47] Otake Y, Soundararajan S, Sengupta TK, et al. Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA. *Blood* 2007;109(7):3069–75. <https://doi.org/10.1182/blood-2006-08-043257>.
- [48] Chen C-M, Chiang S-Y, Yeh N-H. Increased stability of nucleolin in proliferating cells by inhibition of its self-cleaving activity. *J Biol Chem* 1991;266(12):7754–8. [https://doi.org/10.1016/S0021-9258\(20\)89514-3](https://doi.org/10.1016/S0021-9258(20)89514-3).
- [49] Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. *J Clin Invest* 2005;115(3):755–64. <https://doi.org/10.1172/JCI23409> PMID: 15711642.
- [50] Johnston HE, Carter MJ, Larrayoz M, et al. Proteomics profiling of CLL versus healthy B-cells identifies putative therapeutic targets and a subtype-independent signature of spliceosome dysregulation. *Mol Cell Proteomics* 2018;17(4):776–91. <https://doi.org/10.1074/mcp.RA117.000539> PMID: 29367434.
- [51] Bracken CP, Wall SJ, Barré B, et al. Regulation of cyclin D1 RNA stability by SNIP1. *Cancer Res* 2008;68(18):7621–8. <https://doi.org/10.1158/0008-5472.CAN.08-1217> PMID: 18794151.
- [52] Abboudi Z, Patel K, Naresh KN. Cyclin D1 expression in typical chronic lymphocytic leukaemia. *Eur J Haematol* 2009;83(3):203–7. <https://doi.org/10.1111/j.1600-0609.2009.01276.x> PMID: 19467018.
- [53] Damle RN, Batliwalla FM, Ghiotto F, et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. *Blood* 2004;103(2):375–82. <https://doi.org/10.1182/blood-2003-04-1345> PMID: 14504108.
- [54] Mailand N, Lukas C, Kaiser BK, et al. Deregulated human Cdc14A phosphatase disrupts centrosome separation and chromosome segregation. *Nat Cell Biol* 2002;4(4):318–22. <https://doi.org/10.1038/ncb777> PMID: 11901424.
- [55] Kong X-x, Lv Y-r, Shao L-p, et al. HBx-induced MiR-1269b in NF- $\kappa$ B dependent manner upregulates cell division cycle 40 homolog (CDC40) to promote proliferation and migration in hepatoma cells. *J Transl Med* 2016;14(1):189. <https://doi.org/10.1186/s12967-016-0949-y> PMID: 27349221.
- [56] Grill B, Wilson GM, Zhang K-X, et al. Activation/division of lymphocytes results in increased levels of cytoplasmic activation/proliferation-associated protein-1: prototype of a new family of proteins. *J Immunol* 2004;172(4):2389–400. <https://doi.org/10.4049/jimmunol.172.4.2389> PMID: 14764709.
- [57] Saffin J-M, Venoux M, Prigent C, et al. ASAP, a human microtubule-associated protein required for bipolar spindle assembly and cytokinesis. *Proc Natl Acad Sci* 2005;102(32):11302–7. <https://doi.org/10.1073/pnas.0500964102> PMID: 16049101.
- [58] Touat M, Ileana E, Postel-Vinay S, et al. Targeting FGFR signaling in cancer. *Clin Cancer Res* 2015;21(12):2684–94. <https://doi.org/10.1158/1078-0432.CCR-14-2329> PMID: 26078430.
- [59] Song Z, Lu P, Furman RR, et al. Activities of SYK and PLC $\gamma$ 2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. *Clin Cancer Res* 2010;16(2):587–99. <https://doi.org/10.1158/1078-0432.CCR-09-1519> PMID: 20068106.
- [60] Zhou J-D, Yao D-M, Li X-X, et al. KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia. *Oncotarget* 2017;8(39):66087. <https://doi.org/10.18632/oncotarget.19798> PMID: 29029494.
- [61] Jamalpour M, Li X, Cavelier L, et al. Tumor SHB gene expression affects disease characteristics in human acute myeloid leukemia. *Tumor Biol* 2017;39(10). <https://doi.org/10.1177/1010428317720643> PMID: 28982308.
- [62] Dutta B, Ren Y, Hao P, et al. Profiling of the chromatin-associated proteome identifies hp1bp3 as a novel regulator of cell cycle progression. *Mol Cell Proteomics* 2014;13(9):2183–97. <https://doi.org/10.1074/mcp.M113.034975> PMID: 24830416.
- [63] Dutta B, Yan R, Lim SK, et al. Quantitative profiling of chromatinome dynamics reveals a novel role for HP1BP3 in hypoxia-induced oncogenesis. *Mol Cell Proteomics* 2014;13(12):3236–49. <https://doi.org/10.1074/mcp.M114.038232> PMID: 25100860.
- [64] Pepper C, Hewamana S, Brennan P, et al. NF- $\kappa$ B as a prognostic marker and therapeutic target in chronic lymphocytic leukemia. *Future Oncol* 2009;5(7):1027–37. <https://doi.org/10.2217/fon.09.72> PMID: 19792971.